Biomea Fusion, Inc. - 8-K Filing
Biomea Fusion reported Q1 2026 financial results on May 11, 2026, showing $45.1 million in cash reserves as of March 31 and a net loss of $12.4 million for the quarter (vs. $29.3 million in same period last year). R&D expenses were $9.1 million compared to $22.9 million in Q1 2025, driven by reduced clinical costs and headcount. The company also provided updates on its drug candidates: icovamenib advanced into chronic dosing trials for T1D/T2D with Phase II data expected in late 2026; BMF-650's Phase I obesity trial is ongoing with initial weight reduction results anticipated in Q2. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $BMEA